Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. DOI: 10.12290/xhyxzz.2022-0089
Citation: Chinese Society of Nuclear Medicine, Chinese Society of Molecular Imaging in Chinese Biophysical Society. Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 227-234. DOI: 10.12290/xhyxzz.2022-0089

Expert Consensus on Clinical Application of Integrin RGD Receptor Imaging (2022)

Funds: 

National Natural Science Foundation of China 81871392

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-016

The Capital Health Development Scientific Research Project 2018-1-4011

Emergency Key Program of Guangzhou Laboratory EKPG21-16

CAMS Clinical and Translational Medicine Research Fund 2019XK320032

More Information
  • Corresponding authors: ZHU Zhaohui1, 2, E-mail: zhuzhh@pumch.cn
    LI Sijin3, E-mail: lisjnm123@163.com
    WANG Fan4, E-mail: wangfan@bjmu.edu.cn
    1. Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    2. State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
    3. Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan 030001, China
    4. Medical Isotopes Research Center, Peking University, Beijing 100191, China

  • Received Date: February 26, 2022
  • Accepted Date: March 14, 2022
  • Issue Publish Date: March 29, 2022
  • Integrin is a group of transmembrane glycoprotein that mediates cell-cell adhesion and signal transduction. It regulates cell adhesion, migration, proliferation, apoptosis and other functions. It is highly expressed on the surface of neovascular endothelial cells and a variety of malignant tumor cells. The peptides witharginine-glycine-aspartate (RGD) motif can specifically bind to multiplesubtypes of integrin including αVβ3. When labeled with radionuclides for single photon emission tomography (SPECT) or positron emission tomography (PET), the RGD-based peptides can non-invasively reveal the tumor characteristics, including invasion and metastasis, as well as evaluate angiogenesis in vivo. These methods have shown strong value in clinical application. Based on the home-and-abroad progress in relevant clinical research, this expert consensus aims to establish principles for clinical application of RGD-based peptides to integrin imaging.
  • [1]
    Ludwig BS, Kessler H, Kossatz S, et al. RGD-binding integrins revisited: how recently discovered functions and novel synthetic ligands (re-)shape an ever-evolving field[J]. Cancers (Basel), 2021, 13: 1711. DOI: 10.3390/cancers13071711
    [2]
    Kossatz S, Beer AJ, Notni J. It's time to shift the paradigm: translation and clinical application of non-alphavbeta3 integrin targeting radiopharmaceuticals[J]. Cancers (Basel), 2021, 13: 5958. DOI: 10.3390/cancers13235958
    [3]
    Steiger K, Quigley NG, Groll T, et al. There is a world beyond alphavbeta3-integrin: multimeric ligands for imaging of the integrin subtypes alphavbeta6, alphavbeta8, alphav-beta3, and alpha5beta1 by positron emission tomography[J]. EJNMMI Res, 2021, 11: 106. DOI: 10.1186/s13550-021-00842-2
    [4]
    Ebenhan T, Kleynhans J, Zeevaart JR, et al. Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 1414-1433. DOI: 10.1007/s00259-020-04975-9
    [5]
    Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3[J]. Theranostics, 2016, 6: 78-92. DOI: 10.7150/thno.13242
    [6]
    Zhu Z, Miao W, Li Q, et al. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study[J]. J Nucl Med, 2012, 53: 716-722. DOI: 10.2967/jnumed.111.098988
    [7]
    Fu J, Xie Y, Fu T, et al. [(99m)Tc]Tc-Galacto-RGD(2) integrin alpha(v)beta(3)-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data[J]. EJNMMI Res, 2021, 11: 59. DOI: 10.1186/s13550-021-00801-x
    [8]
    Verjans J, Wolters S, Laufer W, et al. Early molecular imaging of interstitial changes in patients after myocardial infarction: Comparison with delayed contrast-enhanced magnetic resonance imaging[J]. J Nucl Cardiol, 2010, 17: 1065-1072. DOI: 10.1007/s12350-010-9268-5
    [9]
    Mi B, Yu C, Pan D, et al. Pilot prospective evaluation of (18)F-Alfatide Ⅱ for detection of skeletal metastases[J]. Theranostics, 2015, 5: 1115-1121. DOI: 10.7150/thno.12938
    [10]
    Dong Y, Wei Y, Chen G, et al. Relationship between clinicopathological characteristics and PET/CT uptake in esophageal squamous cell carcinoma: [(18)F]Alfatide versus[(18)F]FDG[J]. Mol Imaging Biol, 2019, 21: 175-182. DOI: 10.1007/s11307-018-1216-9
    [11]
    Zheng K, Liang N, Zhang J, et al. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer[J]. J Nucl Med, 2015, 56: 1823-1827. DOI: 10.2967/jnumed.115.160648
    [12]
    Kim YI, Phi JH, Paeng JC, et al. In vivo evaluation of angiogenic activity and its correlation with efficacy of indirect revascularization surgery in pediatric moyamoya disease[J]. J Nucl Med, 2014, 55: 1467-1472. DOI: 10.2967/jnumed.114.142430
    [13]
    Iagaru A, Mosci C, Mittra E, et al. Glioblastoma multiforme recurrence: an exploratory study of (18)F-FPPRGD2 PET/CT[J]. Radiology, 2015, 277: 497-506. DOI: 10.1148/radiol.2015141550
    [14]
    Chen SH, Wang HM, Lin CY, et al. RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 1621-1629. DOI: 10.1007/s00259-016-3345-1
    [15]
    Beer AJ, Pelisek J, Heider P, et al. PET/CT imaging of integrin αVβ3 expression in human carotid atherosclerosis[J]. JACC Cardiovasc Imaging, 2014, 7: 178-187. DOI: 10.1016/j.jcmg.2013.12.003
    [16]
    Roesch S, Lindner T, Sauter M, et al. Comparison of the RGD motif-containing αVβ6 integrin-binding peptides SFLAP3 and SFITGv6 for diagnostic application in HNSCC[J]. J Nucl Med, 2018, 59: 1679-1685. DOI: 10.2967/jnumed.118.210013
    [17]
    Feng X, Wang Y, Lu D, et al. Clinical translation of a (68)Ga-labeled integrinalpha(v)beta(6)-targeting cyclic radiotracer for PET imaging of pancreatic cancer[J]. J Nucl Med, 2020, 61: 1461-1467. DOI: 10.2967/jnumed.119.237347
    [18]
    Quigley NG, Steiger K, Hoberück S, et al. PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the "Cancer Integrin" alphavbeta6 with Ga-68-Trivehexin[J]. Eur J Nucl Med Mol Imaging, 2021, 24: 1-12.
    [19]
    Kimura RH, Wang L, Shen B, et al. Evaluation of integrin alpha v beta(6) cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis[J]. Nat Commun, 2019, 10: 4673. DOI: 10.1038/s41467-019-11863-w
    [20]
    Hausner SH, Bold RJ, Cheuy LY, et al. Preclinical development and first-in-human imaging of the integrin alphavbeta6 with[18F]alphavbeta6-binding peptide in metastatic carcinoma[J]. Clin Cancer Res, 2019, 25, 1206-1215.
    [21]
    Sharma R, Valls PO, Inglese M, et al. [(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 1239-1251. DOI: 10.1007/s00259-019-04532-z
    [22]
    Zheng Y, Wang H, Tan H, et al. Evaluation of lung cancer and neuroendocrine neoplasm in a single scan by targeting both somatostatin receptor and integrin αVβ3[J]. Clin Nucl Med, 2019, 44: 687-694. DOI: 10.1097/RLU.0000000000002680
    [23]
    Zhang J, Mao F, Niu G, et al. (68)Ga-BBN-RGD PET/CT for GRPR and integrin alphavbeta3 imaging in patients with breast cancer[J]. Theranostics, 2018, 8: 1121-1130. DOI: 10.7150/thno.22601
    [24]
    Liolios C, Sachpekidis C, Kolocouris A, et al. PET diagnostic molecules utilizing multimeric cyclic RGD peptide analogs for imaging integrin alpha(v)beta(3) receptors[J]. Molecules, 2021, 26: 1792. DOI: 10.3390/molecules26061792
    [25]
    Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression[J]. Eur J Nucl Med Mol Imaging, 2007, 34: 1823-1831. DOI: 10.1007/s00259-007-0427-0
    [26]
    Chen H, Jacobson O, Niu G, et al. Novel "add-On" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostics agents[J]. J Nucl Med, 2017, 58: 590-597. DOI: 10.2967/jnumed.116.182097
    [27]
    Li D, Zhao X, Zhang L, et al. (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study[J]. Mol Pharm, 2014, 11: 3923-3929. DOI: 10.1021/mp5003224
    [28]
    Kang F, Wang Z, Li G, et al. Inter-heterogeneity and intra-heterogeneity of alpha(v)beta(3) in non-small cell lung cancer and small cell lung cancer patients as revealed by (68)Ga-RGD(2) PET imaging[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 1520-1528. DOI: 10.1007/s00259-017-3696-2
    [29]
    Tonnelet D, Bohn MDP, Becker S, et al. Angiogenesis imaging study using interim[(18)F]RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence[J]. EJNMMI Res, 2021, 11: 37. DOI: 10.1186/s13550-021-00776-9
    [30]
    Jin X, Liang N, Wang M, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer[J]. Radiology, 2016, 281: 958-966. DOI: 10.1148/radiol.2016150813
    [31]
    Miao W, Zheng S, Dai H, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: A multicenter study[J]. PLoS One, 2014, 9: e111221. DOI: 10.1371/journal.pone.0111221
    [32]
    Li L, Ma L, Shang D, et al. Pretreatment PET/CT imaging of angiogenesis based on (18)F-RGD tracer uptake may predict antiangiogenic response[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 940-947. DOI: 10.1007/s00259-018-4143-8
    [33]
    Sun Y, Zeng Y, Zhu Y, et al. Application of (68)Ga-PRGD2 PET/CT for αVβ3-integrin imaging of myocardial infarction and stroke[J]. Theranostics, 2014, 4: 778-786. DOI: 10.7150/thno.8809
    [34]
    Luo Y, Sun Y, Zhu Z, et al. Is the change of integrin α(v)β(3) expression in the infarcted myocardium related to the clinical outcome?[J]. Clin Nucl Med, 2014, 39: 655-657. DOI: 10.1097/RLU.0000000000000426
    [35]
    Lobeek D, Bouwman FCM, Aarntzen EHJG, et al. A clinical feasibility study to image angiogenesis in patients with arteriovenous malformations using (68)Ga-RGD PET/CT[J]. J Nucl Med, 2020, 61: 270-275. DOI: 10.2967/jnumed.119.231167
    [36]
    Zhu Z, Yin Y, Zheng K, et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using 68Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study[J]. Ann Rheum Dis, 2014, 73: 1269-1272. DOI: 10.1136/annrheumdis-2013-204820
    [37]
    Lukey PT, Coello C, Gunn R, et al. Clinical quantification of the integrin alphavbeta6 by[(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study)[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 967-979. DOI: 10.1007/s00259-019-04586-z
  • Related Articles

    [1]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [2]QIU Luyao, TANG Wenjing, YANG Lu, LYU Ge, CHEN Junjie, SUN Gan, WANG Yanping, ZHOU Lina, AN Yunfei, ZHANG Zhiyong, TANG Xuemei, ZHAO Xiaodong, DU Hongqiang. Clinical Phenotype and Immunological Characteristics of A Patient with De Novo Heterozygous Mutation of PTEN[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 373-378. DOI: 10.12290/xhyxzz.2023-0023
    [3]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [4]Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584
    [5]KONG Linghua, XIAO Xiaoping, WAN Ru, XIANG Yang. Clinical Application of ThinPrep Imaging System in Cervical Cytology[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 613-619. DOI: 10.12290/xhyxzz.2022-0221
    [6]ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180
    [7]Rare Diseases Society of Chinese Research Hospital Association, National Rare Diseases Committee, Beijing Rare Disease Diagnosis, Treatment and Protection Society, Gitelman Syndrome Consensus Working Group. Expert Consensus for the Diagnosis and Treatment of Gitelman Syndrome in China (2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 902-912. DOI: 10.12290/xhyxzz.2021-0555
    [8]Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology. Chinese Expert Consensus on Clinical Application of Human Papilloma Virus Vaccine[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 189-201. DOI: 10.12290/xhyxzz.2021-0082
    [9]Noyes' Knee Disorders: Surgery, Rehabilitation, Clinical Outcomes(2nd ed.)(2016)[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(1): 18-18.
    [10]MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006
  • Cited by

    Periodical cited type(1)

    1. 刘玉文,张丽梅,王永丽,徐小梅,母亚丹,杨志杰,杨树婷,罗凤云. 老年多学科团队服务对共病伴营养不良老年患者的疗效分析. 昆明医科大学学报. 2024(12): 81-87 .

    Other cited types(0)

Catalog

    Article Metrics

    Article views (1421) PDF downloads (441) Cited by(1)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close